ARS Pharmaceuticals, Inc. updated its corporate presentation for use in meetings with investors, analysts and others and announced the positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending the granting of a marketing authorization for the medicinal product EURneffy.